Literature DB >> 27512450

Acidosis: A potential explanation for adverse fetal outcome in intrahepatic cholestasis of pregnancy. A case report.

K Sterrenburg1, W Visser2, L S Smit3, J Cornette1.   

Abstract

BACKGROUND: Intrahepatic cholestasis of pregnancy is a cholestatic disorder with an increased risk for adverse perinatal outcome. The mechanism underlying intrauterine demise is poorly understood. CASE: A nulliparous woman with gestational age of 36 plus 6 weeks presented with suspected intrahepatic cholestasis. Continuous CTG monitoring evolved from a normal pattern towards a non-reassuring pattern. A male neonate was delivered by caesarean section. Apgar scores 0, 1 and 4 at 1, 5 and 10 min. Fetal cord gas analysis showed pH 6.98, base deficit -15 mmol/L. Blood results showed maternal serum bile acid concentration of 220 µmol/L.
CONCLUSION: Our case suggests gradual evolution towards hypoxia and acidosis. It is unknown whether certain components in the bile acid concentrations might contribute to a fetal metabolic component of the acidosis.

Entities:  

Keywords:  High-risk pregnancy; complications

Year:  2014        PMID: 27512450      PMCID: PMC4934989          DOI: 10.1177/1753495X14553649

Source DB:  PubMed          Journal:  Obstet Med        ISSN: 1753-495X


  8 in total

1.  The mechanical PR interval in fetuses of women with intrahepatic cholestasis of pregnancy.

Authors:  Stacy L Strehlow; Bhuvan Pathak; Thomas M Goodwin; Belinda M Perez; Mahmood Ebrahimi; Richard H Lee
Journal:  Am J Obstet Gynecol       Date:  2010-08-03       Impact factor: 8.661

Review 2.  Intrahepatic cholestasis of pregnancy.

Authors:  Victoria Geenes; Catherine Williamson
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

3.  Dating the time interval from meconium passage to birth.

Authors:  P W Miller; R W Coen; K Benirschke
Journal:  Obstet Gynecol       Date:  1985-10       Impact factor: 7.661

4.  The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis.

Authors:  C Williamson; J Gorelik; B M Eaton; M Lab; M de Swiet; Y Korchev
Journal:  Clin Sci (Lond)       Date:  2001-04       Impact factor: 6.124

5.  Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses.

Authors:  Edgar T Jaeggi; Earl D Silverman; Carl Laskin; John Kingdom; Fraser Golding; Roland Weber
Journal:  J Am Coll Cardiol       Date:  2011-03-29       Impact factor: 24.094

6.  Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta.

Authors:  M A Serrano; D Brites; M G Larena; M J Monte; M P Bravo; N Oliveira; J J Marin
Journal:  J Hepatol       Date:  1998-05       Impact factor: 25.083

7.  Vasoconstrictive effect of bile acids on isolated human placental chorionic veins.

Authors:  W H Sepúlveda; C González; M A Cruz; M I Rudolph
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1991-12-13       Impact factor: 2.435

8.  Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates.

Authors:  Anna Glantz; Hanns-Ulrich Marschall; Lars-Ake Mattsson
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

  8 in total
  1 in total

1.  Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.

Authors:  Tharni Vasavan; Sahil Deepak; Indu Asanka Jayawardane; Maristella Lucchini; Catherine Martin; Victoria Geenes; Joel Yang; Anita Lövgren-Sandblom; Paul Townsend Seed; Jenny Chambers; Sophia Stone; Lesia Kurlak; Peter Hendy Dixon; Hanns-Ulrich Marschall; Julia Gorelik; Lucy Chappell; Pam Loughna; Jim Thornton; Fiona Broughton Pipkin; Barrie Hayes-Gill; William Paul Fifer; Catherine Williamson
Journal:  J Hepatol       Date:  2020-12-01       Impact factor: 25.083

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.